SCHEMBL24664355

SCHEMBL24664355

Cc1cnc(Nc2ccc(N3CCC4(CC3)CNC4)c(F)c2)nc1-c1cnn(C(C)C)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 18/20 0.65
TYK2 P29597 13/20 0.65
FLT3 P36888 6/20 0.65
JAK1 P23458 6/20 0.65
JAK3 P52333 5/20 0.65
CYP1A2 P05177 1/20 0.65
LCK P06239 1/20 0.65
LYN P07948 1/20 0.65
CYP2C9 P11712 1/20 0.65
CDK4 P11802 1/20 0.65
FLT1 P17948 1/20 0.65
CCND3 P30281 1/20 0.65
CYP2C19 P33261 1/20 0.65
FLT4 P35916 1/20 0.65
CDK6 Q00534 1/20 0.65
KCNH2 Q12809 1/20 0.65
AXL P30530 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29608312 1.00 JAK2 (0.65) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24664521 0.91 JAK2 (0.65) JAK2TYK2FLT3JAK1JAK3
SCHEMBL22852546 0.91 JAK2 (0.65) JAK2TYK2FLT3JAK1JAK3
SCHEMBL22852642 0.90 JAK2 (0.69) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24664499 0.89 JAK2 (0.65) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24663796 0.88 JAK2 (0.66) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24664527 0.88 JAK2 (0.65) JAK2TYK2FLT3JAK1JAK3
SCHEMBL29608225 0.87 JAK2 (0.75) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24664433 0.87 JAK2 (0.75) JAK2TYK2FLT3JAK1JAK3
SCHEMBL24664356 0.87 JAK2 (0.68) JAK2TYK2FLT3JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2022-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JAK2, FLT3, JAK1 JAK2 1/4885TYK2 15/4885FLT3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.